|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1-2
|
|
pubmed:dateCreated |
2003-9-26
|
|
pubmed:abstractText |
We have studied the role of the chemokine receptor CCR1 during the effector stage of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in DA rats. In situ hybridization histochemistry revealed local production of the CCR1 ligands CCL3 (MIP-1 alpha) and CCL5 (RANTES), as well as large numbers of CCR1 and CCR5 expressing cells within inflammatory brain lesions. A low-molecular weight CCR1 selective antagonist potently abrogated both clinical and histopathological disease signs during a 5-day treatment period, without signs of peripheral immune compromise. Thus, we demonstrate therapeutic targeting of CCR1-dependent leukocyte recruitment to the central nervous system in a multiple sclerosis (MS)-like rat model.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2,2-diphenyl-(5-(4-chlorophenyl)pipe...,
http://linkedlifedata.com/resource/pubmed/chemical/Ccr1 protein, rat,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokines, CC,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Myelin Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Myelin-Associated Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/Nitriles,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CCR1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Chemokine,
http://linkedlifedata.com/resource/pubmed/chemical/myelin oligodendrocyte glycoprotein
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0165-5728
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
142
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
75-85
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:14512166-Animals,
pubmed-meshheading:14512166-Cell Migration Inhibition,
pubmed-meshheading:14512166-Chemokines, CC,
pubmed-meshheading:14512166-Disease Models, Animal,
pubmed-meshheading:14512166-Drug Administration Schedule,
pubmed-meshheading:14512166-Encephalomyelitis, Autoimmune, Experimental,
pubmed-meshheading:14512166-Female,
pubmed-meshheading:14512166-Immunosuppressive Agents,
pubmed-meshheading:14512166-Injections, Subcutaneous,
pubmed-meshheading:14512166-Lymphoproliferative Disorders,
pubmed-meshheading:14512166-Multiple Sclerosis,
pubmed-meshheading:14512166-Myelin Proteins,
pubmed-meshheading:14512166-Myelin-Associated Glycoprotein,
pubmed-meshheading:14512166-Nitriles,
pubmed-meshheading:14512166-Piperazines,
pubmed-meshheading:14512166-Rats,
pubmed-meshheading:14512166-Receptors, CCR1,
pubmed-meshheading:14512166-Receptors, Chemokine
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease.
|
|
pubmed:affiliation |
Neuroimmunology Unit, Department of Medicine, Karolinska Institutet, SE-171 76 Stockholm, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
